Impact of catheter-directed thrombolysis on the socio-economic burden of pulmonary embolism in Germany: a cost-effectiveness analysis
Authors:
- Katharina MohrKMKatharina Mohr
- Konstantinos C ChristodoulouKCKonstantinos C Christodoulou
- Stefano BarcoSBStefano Barco
- Luca ValerioLVLuca Valerio
- Thomas NeusiusTNThomas Neusius
- Karsten KellerKarsten Keller
- Lukas HobohmLHLukas Hobohm
- Markus VosselerMVMarkus Vosseler
- Timo UphausTUTimo Uphaus
- Marianne HahnMHMarianne Hahn
- Frederikus A KlokFKFrederikus A Klok
- Harald BinderHBHarald Binder
Open Access
- 19 January 2026
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (4) , 516-525
Abstract
Aims: Catheter-directed treatment has yielded promising results in acute pulmonary embolism (PE), but state-of-the-art health economic evaluation of interventional treatment options is needed for healthcare systems to endorse its integration into clinical practice. We sought to provide an evidence-based comprehensive evaluation of the cost-effectiveness of catheter-directed thrombolysis (CDT) in PE. Methods and results: A systematic review and meta-analysis were conducted to retrieve outcomes of patients with intermediate- or high-risk PE treated with CDT vs. standard of care (SoC). A cost-effectiveness analysis model was developed, comparing CDT with SoC from the healthcare provider’s (payer’s) and the societal perspective in Germany (population of 84 million). A dynamic budget impact analysis (BIA) model was applied, assuming gradually increasing adoption of CDT. Over a 5-year time horizon, CDT resulted in 4.13 life-years (LY) and 3.58 quality-adjusted life years (QALY), compared with 3.90 LY and 3.38 QALY with SoC. From the payer’s perspective, the incremental cost-utility ratio (ICUR) for CDT was €27 349 per QALY. From the societal perspective, costs were lower for CDT than for SoC (€33 313 vs. €37 501). Cost-effectiveness of CDT was confirmed when focusing on patients with intermediate-risk PE; it also persisted when only randomized controlled trials were considered. Probabilistic analysis confirmed the robustness of the model. Budget impact analysis showed that, despite the higher upfront treatment costs of CDT in the acute phase, cost savings can be expected in the long term. Conclusion: In selected patients with acute PE, catheter-directed interventions may improve patient outcomes while remaining within the acceptable cost-effectiveness threshold.Keywords
Funding Information
- University Medical Center of the Johannes Gutenberg University Mainz
- CERGAS
- SDA Bocconi School of Management
This publication has 42 references indexed in Scilit:
- Economic Analysis of Catheter‐Directed Thrombolysis for Intermediate‐Risk Pulmonary EmbolismCatheterization and Cardiovascular Interventions, 2024
- Drivers and recent trends of hospitalisation costs related to acute pulmonary embolismClinical Research in Cardiology, 2024
- Burden of Ischemic and Hemorrhagic Stroke Across the US From 1990 to 2019JAMA Neurology, 2024
- A Model-Based Estimate of the Cost-Effectiveness Threshold in GermanyApplied Health Economics and Health Policy, 2023
- Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysisJournal of Thrombosis and Thrombolysis, 2021
- Disability-Adjusted Life-Years Associated With Intracerebral Hemorrhage and Secondary InjuryJAMA Network Open, 2021
- Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015JAMA, 2019
- Improving the Methods for the Economic Evaluation of Medical DevicesHealth Economics, 2017
- Estimating Quality of Life in Acute Venous ThrombosisJAMA Internal Medicine, 2013
- Redefining Health Care: Creating Value-Based Competition on ResultsAtlantic Economic Journal, 2007